There are currently 929 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University Health System. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
NCT04839705
Recruiting
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Duke University, Durham, North Carolina
Conditions: Wide Neck Bifurcation Intracranial Aneurysms
Register for Updates
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
NCT05382208
Recruiting
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of ant... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/13/2025
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: Emphysema, HIV
Register for Updates
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
NCT05708352
Recruiting
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-si... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Duke University, Durham, North Carolina
Conditions: Glioblastoma Multiforme
Register for Updates
Tocilizumab in Lung Transplantation
NCT06033196
Recruiting
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance i... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
06/13/2025
Locations: Duke University Medical Center (Site #: 71139), Durham, North Carolina
Conditions: Lung Transplant
Register for Updates
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
Recruiting
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Zai Lab Site 2018, Durham, North Carolina
Conditions: SCLC
Register for Updates
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702
Recruiting
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransfe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: MTAP-deleted Solid Tumors
Register for Updates
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
NCT06679855
Recruiting
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Gender:
ALL
Ages:
3 months and below
Trial Updated:
06/13/2025
Locations: Duke University, Durham, North Carolina
Conditions: Post-ligation Cardiac Syndrome
Register for Updates
Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors
NCT06732375
Recruiting
The purpose of this study is to evaluate the feasibility and acceptability of the Mindset Moments™ (MM™) program in managing psychological distress and resiliency in adolescent and young adult cancer survivors. Study participation will involve attending 8 weekly, one hour, live online group sessions and completing daily 5 minute activities such as guided imageries and CBT check in within the app. Participants will also be asked to complete an online survey at the time of enrollment and at 4 and... Read More
Gender:
ALL
Ages:
Between 19 years and 25 years
Trial Updated:
06/13/2025
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Cancer, Youth Cancer, Young Adult Cancer, Distress, Psychological
Register for Updates
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/12/2025
Locations: Duke University, Durham, North Carolina
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Register for Updates
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Register for Updates
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
NCT06300411
Recruiting
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Breast Cancer
Register for Updates
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)
NCT06404060
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: All sites listed under NCT06404047, Durham, North Carolina
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates